Purpose: To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI). Material and Methods: A total of 33 patients successfully treated with PTRA (PTRA group, mean age 70 +/- 12 years, 23 female, basal creatinine 1.46 +/- 0.79, range 0.7-4.9 mg/dl) were compared with 33 patients undergoing successful PCI (PCI group), matched for basal creatinine (1.44 +/- 0.6, range 0.7-3.4 mg/dl), gender, and age. In both groups postprocedural (48 h) serum creatinine was measured. Results: Postprocedural creatinine level decreased nonsignificantly in the PTRA group (1.46 +/- 0.8 vs. 1.34 +/- 0.5 mg/dl, P=NS) and increased significantly in the PCI group (1.44 +/- 0.6 vs. 1.57 +/- 0.7 mg/dl, P < 0.02). Changes in serum creatinine after intervention (after-before) were significantly different between the PTRA and PCI groups (-0.12 +/- 0.5 vs. 0.13 +/- 0.3, P=0.014). This difference was not related to either a different clinical risk profile or to the volume of CM administered. Conclusion: In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients. The effectiveness of PTRA on renal function seems to be barely influenced by CM toxicity.
Contrast medium nephrotoxicity after renal artery and coronary angioplasty
FOMMEI, ENZA;
2010-01-01
Abstract
Purpose: To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI). Material and Methods: A total of 33 patients successfully treated with PTRA (PTRA group, mean age 70 +/- 12 years, 23 female, basal creatinine 1.46 +/- 0.79, range 0.7-4.9 mg/dl) were compared with 33 patients undergoing successful PCI (PCI group), matched for basal creatinine (1.44 +/- 0.6, range 0.7-3.4 mg/dl), gender, and age. In both groups postprocedural (48 h) serum creatinine was measured. Results: Postprocedural creatinine level decreased nonsignificantly in the PTRA group (1.46 +/- 0.8 vs. 1.34 +/- 0.5 mg/dl, P=NS) and increased significantly in the PCI group (1.44 +/- 0.6 vs. 1.57 +/- 0.7 mg/dl, P < 0.02). Changes in serum creatinine after intervention (after-before) were significantly different between the PTRA and PCI groups (-0.12 +/- 0.5 vs. 0.13 +/- 0.3, P=0.014). This difference was not related to either a different clinical risk profile or to the volume of CM administered. Conclusion: In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients. The effectiveness of PTRA on renal function seems to be barely influenced by CM toxicity.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
